Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-GDP plus PD-1 mAb in R/R PTCL and AITL
NCT05821192Unknown
- Start
- Mar 2023
- Primary completion
- Apr 2023
- Countries
- 1
01
Overview
Open-label, single-arm trial of PD-1 Monoclonal Antibody in peripheral T-cell lymphoma (PTCL) and angioimmunoblastic T-cell lymphoma (AITL). Primary endpoint: Objective Response Rate at 16 months. Status: unknown.
02
Drugs
PD-1 Monoclonal Antibody
03
Conditions
peripheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on NCT05821192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05821192.